DMB‐driven GSDMD activation and GSDMD overexpression with plasmids substantially attenuated miR‐5119′s inhibitory effects on NET formation (Figure 10b–e), and compromised its therapeutic efficacy in alleviating colitis (Figure 10f–n). The gene discussed is GSDMD; the disease is colitis.